Menu
Not yet recruiting NCT06696690

The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients With Cardiac Arrest

No phase Interventional Median Nerve Coma Post Cardiac Arrest Brain Injury

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: MNS, Sham stimulation.
Who it may be relevant to
Registry conditions: Median Nerve, Coma, Post Cardiac Arrest Brain Injury. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients With Cardiac Arrest: A Multicenter, Prospective, Randomized Controlled Study

Overview

Median nerve stimulation (MNS), a non-invasive brain stimulation technique, has been widely adopted in clinical arousal therapies and multiple clinical investigations have attested to the efficacy of this technique; nevertheless, evidence concerning the application of MNS in improving the neurological prognosis of patients with return of spontaneous circulation (ROSC) following cardiac arrest (CA) remains scarce. The current study endeavors to assess the safety and efficacy of MNS treatment in enhancing the neurological prognosis of CA patients after ROSC and it is designed as a multicenter, prospective, randomized controlled trial with an estimated sample size of 400 patients. Eligible patients will be randomly allocated in a 1:1 ratio to either receive MNS treatment or sham stimulation treatment for 8 hours per day for 14 consecutive days and the primary outcome measure is the proportion of patients in each group with a Cerebral Performance Category (CPC) score ranging from 1 to 2, 6 months after randomization, which will help to determine the effectiveness of MNS in providing neuroprotection for patients with ROSC after CA.

Interventions

  • Device MNS
    The MNS treatment group use the NeuroTrac™ Multi-TENS transcutaneous electrical stimulator to provide an asymmetric biphasic pulse train with a frequency of 35 Hz, an amplitude of 20 mA and a pulse width of 300 ms, which is on for 20 seconds and off for 50 seconds. The treatment lasts for 8 hours per day and the treatment course lasts for one week.
  • Device Sham stimulation
    The sham stimulation treatment group utilized the same stimulation device and was subjected to a safe yet ineffective stimulation protocol for sham stimulation. The treatment lasts for 8 hours per day and the treatment course lasts for 14 days.

Primary outcome measures

  • The proportion of patients with a CPC score of 1-2 [Time frame: 180 days]

Eligibility criteria

Inclusion criteria

  • Age ≥ 18 years old.
  • Hemodynamics remains continuously stable for ≥ 7 days.
  • There is still a lack of purposeful movements after the return of spontaneous circulation following cardiopulmonary resuscitation.
  • Advanced life support is provided within 6 hours after the return of spontaneous circulation (ROSC).

Exclusion criteria

  • Patients with hemodynamic instability.
  • Pregnant patients.
  • Those who have abnormal anatomical structures on the median nerve conduction pathway and are unable to receive electrical stimulation.
  • Patients with a confirmed history of epilepsy before admission or during hospitalization.
  • Patients with severe arrhythmia or those who have pacemakers implanted.
  • Patients whose family members do not agree to their enrollment in the study.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

China · 1 center
  • Beijing Chao-Yang Hospital — Beijing

Identifiers

NCT: NCT06696690 · 2024-6-7-3

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗